Screener
Indivior Pharmaceuticals, Inc. INDV EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Indivior Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
FAQ
- What is Indivior Pharmaceuticals, Inc.'s EBITDA margin?
- Indivior Pharmaceuticals, Inc. (INDV) reported EBITDA margin of 26.5% in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s EBITDA margin increased by 621.4% year-over-year, from 3.7% to 26.5%.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s EBITDA margin?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s EBITDA margin has grown at a 48.0% compound annual growth rate (CAGR), from -6.8% to 21.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Indivior Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude